A retrospective cohort study of Talimogene Laherparepvec in Unresectable Stage IIIB-D Melanoma patients
Latest Information Update: 15 Jun 2021
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Jun 2021 New trial record
- 05 Jun 2021 Results (data cut off: 31 Aug 2020) published in the European Journal of Cancer.